AR067502A1 - Pelets de administracion oral y liberacion retardada de clorhidrato de duloxetina - Google Patents

Pelets de administracion oral y liberacion retardada de clorhidrato de duloxetina

Info

Publication number
AR067502A1
AR067502A1 ARP080102970A ARP080102970A AR067502A1 AR 067502 A1 AR067502 A1 AR 067502A1 AR P080102970 A ARP080102970 A AR P080102970A AR P080102970 A ARP080102970 A AR P080102970A AR 067502 A1 AR067502 A1 AR 067502A1
Authority
AR
Argentina
Prior art keywords
pelets
chlorhydrate
duloxetine
oral administration
delayed delay
Prior art date
Application number
ARP080102970A
Other languages
English (en)
Inventor
Perez Sergio Lloret
Pena Agnes Fernandez
Original Assignee
Combino Pharm Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combino Pharm Sl filed Critical Combino Pharm Sl
Publication of AR067502A1 publication Critical patent/AR067502A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procesos para la elaboracion y el uso de los mismos. Reivindicacion 1: Un pélet de clorhidrato de duloxetina de liberacion retardada caracterizado porque comprende: i) un nucleo inerte; (ii) una primera capa que contiene clorhidrato de duloxetina y opcionalmente uno o más excipientes aceptables para uso farmacéutico; (iii) una capa intermedia que comprende un polímero derivado de celulosa y opcionalmente uno o más excipientes aceptables para uso farmacéutico; y (iv) una capa entérica que comprende un polímero entérico y opcionalmente uno o más excipientes aceptables para uso farmacéutico.
ARP080102970A 2007-07-09 2008-07-10 Pelets de administracion oral y liberacion retardada de clorhidrato de duloxetina AR067502A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92969707P 2007-07-09 2007-07-09

Publications (1)

Publication Number Publication Date
AR067502A1 true AR067502A1 (es) 2009-10-14

Family

ID=40667910

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102970A AR067502A1 (es) 2007-07-09 2008-07-10 Pelets de administracion oral y liberacion retardada de clorhidrato de duloxetina

Country Status (2)

Country Link
AR (1) AR067502A1 (es)
WO (1) WO2009066181A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2376095B1 (es) * 2008-10-02 2013-01-24 Laboratorios Del Dr. Esteve, S.A. Pellets entéricos de duloxetina.
MX2012003082A (es) * 2009-09-17 2012-04-19 Cadila Healthcare Ltd Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol.
PL224543B1 (pl) 2013-08-21 2017-01-31 Pabianickie Zakłady Farm Polfa Spółka Akcyjna Dojelitowa tabletka duloksetyny

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
DE69721747T2 (de) * 1996-03-11 2004-04-01 Eli Lilly And Co., Indianapolis Methode zur behandlung oder verhütung von interstitieller blasenentzundung
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
JP2008543929A (ja) * 2005-06-20 2008-12-04 カディラ・ヘルスケア・リミテッド デュロキセチンの調節放出型の投与製剤
WO2007139886A2 (en) * 2006-05-22 2007-12-06 Teva Pharmaceutical Industries Ltd. Duloxetine hydrochloride delayed release formulations
EP1938840A1 (en) * 2006-12-27 2008-07-02 LEK Pharmaceuticals D.D. Duloxetine composition
WO2008129501A2 (en) * 2007-04-20 2008-10-30 Wockhardt Research Centre Pharmaceutical compositions of duloxetine

Also Published As

Publication number Publication date
WO2009066181A2 (en) 2009-05-28
WO2009066181A3 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
ES2509117T3 (es) Composición farmacéutica oral que contiene dabigatran etexilato
NO20085332L (no) Duloksetinhydrogenklorid-formuleringer med forsinket frigivelse
CL2014002754A1 (es) Forma de dosis de liberación controlada solida que comprende un nucleo con una primera porcion de un analgesico opioide y una cubierta que encierra el nucleo y comprende una segunda porcion del analgesico opioide; metodo de preparacion; uso en el tratamiento del dolor. (divisional de solicitud n°1450-2014).
AR082091A1 (es) Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion
DK1940364T4 (da) Kapselformulering af pirfenidon og farmaceutisk acceptable excipienser
DE60330909D1 (de) Tablette mit modifizierter freisetzung von bupropion hydrochlorid
AR038527A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
NO20053119D0 (no) Farmasoytiske sarmmensetninger med fentanyl for intranasal administrasjon.
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
PE20051127A1 (es) Comprimido multicapa de telmisartan y ramipril
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
CL2011002643A1 (es) Composicion farmaceutica que comprende r7227, ritonavir y un excipiente farmaceuticamente aceptable; kit para el tratamiento del virus de la hepatitis c.
CO6501159A2 (es) Formulaciones farmaceuticas de liberación controlada de nitazoxanida
NO20084065L (no) Hurtig frigivelses paracetamol tabletter
DE602005021475D1 (de) Magenresistente pharmazeutische dosierform mit n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutaminsäure (lk-423)
DK1711169T3 (da) Coatede mikrodepottabletter med venlafaxinhydrochlorid
HK1112575A1 (en) Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
AR067502A1 (es) Pelets de administracion oral y liberacion retardada de clorhidrato de duloxetina
CL2008000454A1 (es) Un granulo que comprende un nucleo que comprende quetiapina y un agente aglutinante y una capa de recubrimiento que comprende un agente lubricante; procedimiento de preparacion; y composicion farmaceutica.
SM200500011B (it) Una composizione farmaceutica antimicobatterica
DK1848419T3 (da) Injektionspræparater med diclofenac og farmaceutisk acceptable salte deraf
ITMI20061117A1 (it) Una composizione farmaceutica per la somministrazione sublinguale di vaccini metodo per la sua preparazione e sui usi
BRPI0817863A2 (pt) Camada de proteção mecânica para uma forma de dosagem, forma de dosagem sólida famaceuticamente aceitável, comprimido, uso de uma camada de proteção mecânica e métodos para a preparação de camada de proteção mecãnica

Legal Events

Date Code Title Description
FB Suspension of granting procedure